On August 19, the FDA authorized something unusual: a robot that can independently perform one of medicine’s most routine invasive procedures.
Vitestro’s Aletta uses ultrasound to locate a suitable vein and distinguish it from an artery, then carries out the blood-draw workflow, including tourniquet application, needle insertion, tube filling, and bandaging. Rather than requiring one phlebotomist for every patient, a single supervisor can oversee as many as three systems.
The timing makes the authorization even more notable. Just 12 days earlier, ARPA-H awarded MIT spinout Magnendo up to $32 million to develop autonomous robotic navigation for stroke intervention. Compass AI recorded the award on August 7, two weeks after Magnendo announced an $18 million Series A led by Penumbra.
Within two weeks, two very different parts of healthcare pointed toward the same shift: medical robots moving from tools clinicians operate toward systems capable of performing parts of procedures themselves.
The clinical evidence starts with 1,633 patients across three outpatient departments in the Netherlands.
When the system identified a suitable vein and proceeded, first-stick success reached 94.5%. Performance remained strong among groups that can make manual blood collection more challenging, reaching 97.4% for patients with BMI above 30, 93.4% among patients over 65, and 92.7% among those reporting difficult venous access.
Hemolysis occurred in 0.3% of samples, while adverse events occurred at a rate of 0.6% and were all mild. 90% of patients described the pain as comparable to or less than a manual blood draw, and 82% said they would choose robotic blood collection again.
The economic case may be just as important.
The U.S. employs approximately 139,700 phlebotomists, with median annual pay of $43,660 and roughly 18,400 openings expected each year. Employment is projected to grow 6% through 2034. CDRH Director Michelle Tarver framed the authorization around patients facing "delays due to a growing shortage of trained phlebotomists."
Against that backdrop, the ability for one person to supervise three machines becomes central to the commercial proposition.
Capital has followed the opportunity. Compass AI tracked Vitestro closing a $70 million Series B in March 2026 following a $22 million round in April 2024. Investors include Labcorp, Mayo Clinic, Sutter Health, NYBC Ventures, Sonder Capital, Invest-NL, the European Innovation Council, and Intuitive Surgical co-founder Fred Moll.
That last name is particularly interesting.
Platforms such as Intuitive Surgical’s da Vinci and Medtronic’s Hugo are fundamentally teleoperated systems. A surgeon remains in control. Moll helped establish that model and is now backing technology designed to remove the human operator from parts of the procedure entirely.
Compass AI also shows Moll leading a $3.4 million seed investment in Surgical Automations, which is developing autonomous surgical robots for endoscopic procedures, in October 2025.
Aletta’s De Novo authorization gives this transition regulatory significance. A De Novo does not just clear one machine; it creates a classification and writes special controls covering labeling, performance testing, and clinical evaluation. Future devices that fit the classification could potentially pursue 510(k) clearance using the newly established pathway.
There is, however, one number still missing.
Aletta’s 94.5% first-stick success rate applies when the system identifies a suitable vein and proceeds. What has not been publicly established is the proportion of patients the system declines. That rate will help determine whether robotic phlebotomy can handle most patients or primarily streamline easier blood draws while sending more difficult cases back to human staff.
The same autonomy thesis looks different in stroke intervention. There, geography and access to thrombectomy expertise become critical constraints. Compass AI tracks Affluent Medical acquiring autonomous thrombectomy company Artedrone in December 2025, while China’s Aopeng Medical raised a CN¥100 million Series C for fully autonomous interventional robotics in April 2025.
Vitestro is addressing labor economics in the laboratory. Magnendo and others are pursuing access in interventional medicine. The problems are different, but the technological direction is increasingly similar.
Aletta may therefore matter beyond blood collection. Medical robotics has spent decades helping clinicians perform procedures. The next phase may be defined by what the machines can begin performing themselves.
Join the LSI Mailing List
Upcoming Events
17011 Beach Blvd, Suite 500
Huntington Beach, CA 92647
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data